World

1 killed as US military plane crashes off Japan's coast

Nov 30, 2023

Tokyo [Japan], November 30: A US military plane has crashed into waters off the coast of Japan's Yakushima Island in southern Kagoshima prefecture on Wednesday, media reports said.
Reports quoted the Japan Coast Guard as saying that it received information about the crash at around 2.47pm local time. The 10th Regional Coast Guard Headquarters sent patrol boats and helicopters to the site. One person has been found dead at the crash site, according to the Coast Guard spokesperson.
No details about the condition of others who were on board the ill-fated aircraft are known. The CV-22 Osprey's left engine was on fire, Japanese broadcaster NHK reported. It was trying to land at Yakushima Airport when the accident occurred.
The aircraft, which left US Marine Corps' Air Station Iwakuni in Yamaguchi Prefecture, was reportedly bound for the US Kadena Air Base in Okinawa Prefecture. The CV-22 Osprey is a multi-mission, tiltrotor military aircraft with both vertical takeoff and landing and short takeoff and landing capabilities. It is designed to combine the functionality of a conventional helicopter with the long-range, high-speed cruise performance of a turboprop aircraft.
Source: Qatar Tribune

More news

Concept Medical Announces Successful SIRONA Trial Results, Demonstrating Sirolimus-Coated Balloon as a Promising Alternative for PAD Treatment

Tampa (Florida) [US], January 7: Concept Medical Inc., a global leader in innovative drug-delivery technology, proudly reports positive outcomes from the SIRONA (Head-to-Head Comparison of SIROlimus versus Paclitaxel Drug-Eluting BallooNAngioplasty in the Femoropopliteal Artery) RCT, which show that its sirolimus-coated balloons (SCB) (MagicTouch -PTA) provide patency and functional benefits on par with paclitaxel-coated balloons for patients suffering from peripheral artery disease (PAD). The 1-year data was presented by Principal Investigator Prof. Ulf Teichgraber at the TCT USA 2024 conference in a Late-Breaking Clinical Trials Session (LBCT). Coverage by TCTMD has highlighted these findings, underscoring sirolimus-based therapy as a viable new option in femoropopliteal interventions.

Jan 07, 2025